GLYPROLINE PEPTIDE PHARMACODYNAMICS IN RATS IN THE SETTING OF METABOLIC SYNDROME BY THE PARAMETERS OF LIPID METABOLISM AND TROMBOELASTOGRAMMA
https://doi.org/10.33647/2074-5982-15-4-58-66
Abstract
In this study, experimental data on the biological action of glyproline peptides — Pro-Gly-Pro, Pro-ArgPro, Arg-Pro-Gly-Pro and Pro-Gly-Pro-Leu — on the processes of blood coagulation and lipid metabolism were obtained using animal models of metabolic syndrome. Under the conditions of increased blood clotting and hypercholesterolemia, the regulatory peptides under study were administered intranasally for 7 days once every 24 hours. 20 hours after the last peptide administration, thromboelastogram parameters confi rmed the restoration of the functional state of the coagulating and anticoagulant systems. In addition, a simultaneous positive shift in the parameters of lipid metabolism was observed. These changes lasted for 7 days following the withdrawal of the drugs. It is found that the biological action of the peptides under study consists in their simultaneous regulatory impact on the processes of hemostasis and lipid metabolism.
About the Authors
T. Yu. Obergan
Lomonosov Moscow State University
Russian Federation
Russian Federation
Cand. Sci. (Biol.),
119234, Moscow, Leninskie gory str., 1/12
M. G. Lyapina
Lomonosov Moscow State University
Russian Federation
119234, Moscow, Leninskie gory str., 1/12
Russian Federation
119234, Moscow, Leninskie gory str., 1/12
M. E. Grigorjeva
Lomonosov Moscow State University
Russian Federation
Russian Federation
Cand. Sci. (Biol.),
119234, Moscow, Leninskie gory str., 1/12
L. A. Lyapina
Lomonosov Moscow State University
Russian Federation
119234, Moscow, Leninskie gory str., 1/12
Russian Federation
119234, Moscow, Leninskie gory str., 1/12
References
1. Ashmarin I.P. Pathologicheskaja fi siologija i biochimia [Pathological physiology and biochemie]. Мoscow: Eksamen, 2005. 478 p. (In Russian).
2. Аshmarin I.P., Lyapina L.A., Andreeva L.A., Uljanov A.M., Pastorova V.E., Obergan T.Y., et al. Lechebnyi effect gliprolinov Pro-Gly i Pro-Gly-Pro pri rasvitii experimentalnogo insulinzavisimogo diabeta [Medical effect of glyproline Pro-Gly and Pro-Gly-Pro with the developnet of insulin-dependent diabetes]. Tromboz, gemostaz i reologia [Thrombos, Hemostas and Reology]. 2008;34(2):38–43. (In Russian).
3. Barkagan Z.S., Коstyuchenko G.I. Metabolicheski-vospalitelnaya kontseptsiya aterotromboza i novye podkhody k terapii bolnykh [Metabolic-infl ammatory concept of athe rothrombosis and new approaches to the treatment of patients]. Bulleten Sib. otd. Ros. akad. med. nauk [Bull. Siberian branch of the Academy of Med. Sciences]. 2006;2(120):132–138. (In Russian).
4. Kuznik B.I., Khavinson V.Ch., Tarnovskaya S.I., Linjkova N.S. Epigeneticheskoe deystvie regulyatornykh peptidov na tsitokonoviy profi l i sistemy gemostaza [Epigenetic effect of regulatory peptides on cytokine profi le and hemostatic system]. Vestnik gematologii [The Bulletin of Hematology]. 2013;9(2):29–33. (In Russian).
5. Коvaleva O.N., Kravchenko N.A., Ambrosova T.N. Metabolicheskii sindrom: problemy diagnostiki i prognosticheskie kriterii [Metabolic syndrome: diagnostic problems and prognostic criteria]. Vnutrennaya meditsina [Internal Medicine]. 2008;1(7):1–4. (In Russian).
6. Lyapina L.A., Grigorjeva M.E., Obergan T.Y., Shubina T.A. Teoreticheskie I prakticheskie voprosy izuchenia funktsionalnogo sostojania protivosvertivajuschey sistemy [Theoretical and practical issues of studying the functional state of the blood anticoagulation system]. Мoscow: Аdvansed Solutions Publ., 2012. 160 p. (In Russian).
7. Myasoedov N.F., Shubina T.A., Obergan T.Y., Grigorjeva M.E., Andreeva L.A., Lyapina L.A. Profi lakticheskoe gipokholesterinemicheskoe deytvie regulatornogo peptida Pro-Gly-Pro-Leu [Preventive hypocholesterolemic effect of regulatory peptide Pro-Gly-Pro-Leu]. Voprosy pitaniya [Problems of Nutrition]. 2013;82(5):41–45. (In Russian).
8. Andreeva L.A., Myasoedov N.F., Lyapina L.A., Grigor’eva M.E., Obergan T.Y., Shubina T.A. Effect of the PRO-GLY-PRO peptide on hemostasis and lipid metabolism in rats with hypercholesterolemia. Dokl. Biol. Sci. 2013;453(1):333–335.
9. Chiasson J.L., Josse R.G., Gomis R. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–489.
10. Chew G.T., Gan S.K., Watts G.F. Revisiting the metabolic syndrome. MJA. 2006;185(8):445–449.
11. Day K. Metabolic syndrome, or what you will: defi - nitions and epidemiology. Diab. Vasc. Dis. Res. 2007;4(1):32–38.
12. Ikee R., Hamasaki Y., Oka M., Maesato K., Mano T., Moriya H., et al. Clinical: High-density lipoprotein cholesterol and left ventricular mass index in peritoneal dialysis. Perit. Dial. Int. 2008;28:611–616.
13. Jiao J., Han S.F, Zhang W., Xu J.Y., Tong X., Yin X.B., et al. Chronic leucine supplementation improves lipid metabolism in C57BL/6J mice fed with a high-fat/cholesterol diet. Food Nutr. Res. 2016;60:31–34.
14. Ilas J., Hudecz F., Süli-Vargha H., Kikelj D. Peptides and pseudopeptides incorporating D-Phe-Pro-Arg and Arg-Gly-Asp lead sequences as potential antithrombotic agents. J. Pept. Sci. 2008;14(8):946–953.
15. Kong X., Zhang D.Y., Wu H.B., Li F.X. Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats. Biol. Pharm. Bull. 2011;34(5):693–698.
16. Myasoedov N.F., Lyapina L.A., Grigorjeva M.E., Obergan T.Y., Shubina T.A., Andreeva L.A. Мechanism for glyproline protection in hypercholesterolemia. Pathophysiol. 2016;23(1):27–33.
17. Preetha P.P., Devi В.G., Rajamohan Т. Mature coconut water exhibits antidiabetic and antithrombotic potential via L-arginine-nitric oxide pathway in alloxan induced diabetic rats. J. Basic. Clin. Physiol. Pharmacol. 2015;26(6):575–583.
18. Watson T., Arya A., Sulke N., Lip G.Y.H. Antithrombotic therapy: relationship of indices of infl ammation and thrombogenesis to arithmia burden in paroxysmal arterial fi brillation. Chest. 2010;137:869–876.
19. Xiao C., Hsieh J., Adeli K., Lewis G.F. Gut-liver interaction in trig lyceride-rich lipoprotein metabolism. Am. J. Physiol. Endocrin. Metab. 2011;301:E429–E446.
Review
For citations:
Obergan T.Yu., Lyapina M.G., Grigorjeva M.E., Lyapina L.A. GLYPROLINE PEPTIDE PHARMACODYNAMICS IN RATS IN THE SETTING OF METABOLIC SYNDROME BY THE PARAMETERS OF LIPID METABOLISM AND TROMBOELASTOGRAMMA. Journal Biomed. 2019;(4):58-66. (In Russ.) https://doi.org/10.33647/2074-5982-15-4-58-66
Views:
553
Email this article 
